Want to see SG:T14 full AI Analyst Report?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) Income Statement
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Income Statement
Last quarter (Q2 2026), Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S's total revenue was $936.73M, a decrease of 21.63% from the same quarter last year. In Q2, Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S's net income was $220.32M. See Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.92B | $ 7.31B | $ 8.22B | $ 8.25B | $ 6.91B | |
| $ 3.64B | $ 3.52B | $ 3.62B | $ 3.29B | $ 2.76B | |
| $ 1.15B | $ 953.99M | $ 2.49B | $ 2.57B | $ 2.14B | |
| Depreciation and Amortization | $ 115.66M | $ 125.94M | $ 130.13M | $ 116.56M | $ 115.53M |
| $ 2.61B | $ 2.74B | $ 1.26B | $ 1.11B | $ 991.28M | |
| $ 2.49B | $ 2.57B | $ 1.10B | $ 980.05M | $ 866.68M | |
| $ -2.14M | $ 12.06M | $ -1.61M | $ 138.80K | $ 6.13M | |
| $ 2.49B | $ 2.58B | $ 1.10B | $ 980.19M | $ 872.81M | |
| $ 2.13B | $ 2.23B | $ 986.71M | $ 861.79M | $ 769.14M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.77 | $ 2.90 | $ 1.28 | $ 1.12 | $ 1.00 |
| Diluted EPS | $ 2.77 | $ 2.90 | $ 1.28 | $ 1.11 | $ 1.00 |
| Weighted Average Shares Outstanding | 769.32M | 768.87M | 770.87M | 768.87M | 768.87M |
| Weighted Average Shares Outstanding (Diluted) | 769.32M | 768.87M | 770.87M | 776.39M | 768.87M |
Currency in CNY
